Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hadasit Bio HoldingsHSITF 14 Cash Ratio is 0.95 as of Dec. 2025, which is 87% below its 10-year median of 7.15. GuruFocus rates HSITF with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,381 Biotechnology companies, Hadasit Bio Holdings ranks worse than 73.93% on this metric.
Hadasit Bio Holdings has a Cash Ratio of 0.95. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Hadasit Bio Holdings's Cash Ratio or its related term are showing as below:
HSITF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.82 Med: 7.15 Max: 33.39
Current: 0.95
During the past 13 years, Hadasit Bio Holdings's highest Cash Ratio was 33.39. The lowest was 0.82. And the median was 7.15.
HSITF's Cash Ratio is ranked worse than 73.93% of 1381
companies
in the Biotechnology industry
Industry Median: 2.96
vs HSITF: 0.95
Hadasit Bio Holdings (OTCPK:HSITF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Hadasit Bio Holdings Cash Ratio Related Terms
Hadasit Bio Holdings Cash Ratio Historical Data
* Premium members only.
The historical data trend for Hadasit Bio Holdings's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Hadasit Bio Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hadasit Bio Holdings Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hadasit Bio Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Hadasit Bio Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hadasit Bio Holdings (HSITF) has a Cash Ratio of 0.95 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Hadasit Bio Holdings and its competitors. This is 87% below median its historical median of 7.15. Over the past decade, Hadasit Bio Holdings' Cash Ratio has ranged from 0.82 to 33.39. According to the industry distribution chart, Hadasit Bio Holdings ranks #1021 out of 1381 companies in the Biotechnology industry, placing it in the top 73.9%.
Is Hadasit Bio Holdings' Cash Ratio too high?
Hadasit Bio Holdings' current Cash Ratio of 0.95 is 87% below median its 10-year median of 7.15. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 33.39. The Biotechnology industry median Cash Ratio is 2.96. Hadasit Bio Holdings' value of 0.95 is 67.9% below this industry median. Based on the distribution chart, Hadasit Bio Holdings ranks #1021 out of 1381 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hadasit Bio Holdings has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Hadasit Bio Holdings' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hadasit Bio Holdings ranks #1021 out of 1381 companies for Cash Ratio. This places Hadasit Bio Holdings in the lower half of its industry. The industry median Cash Ratio is 2.96. Hadasit Bio Holdings' value of 0.95 is 67.9% below this benchmark. Historically, Hadasit Bio Holdings' own Cash Ratio has ranged from 0.82 to 33.39 over the past decade. While the company's 10-year median is 7.15 vs. the industry median of 2.96, Hadasit Bio Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hadasit Bio Holdings's current Cash Ratio of 0.95 is 67.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Hadasit Bio Holdings and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hadasit Bio Holdings's current Cash Ratio is 0.95, which is 87% below median its own 10-year median of 7.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hadasit Bio Holdings stock overvalued right now?
Hadasit Bio Holdings (HSITF) has a current Cash Ratio of 0.95. The current Cash Ratio is 0.95, which is 87% below median its 10-year median of 7.15 and 67.9% below the Biotechnology industry median of 2.96. Hadasit Bio Holdings' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Hadasit Bio Holdings (HSITF), the current Cash Ratio is 0.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hadasit Bio Holdings Ltd serves as a precedent in the field of biotech financing. It is engaged in the advancement and enhancement of its portfolio companies. Its portfolio companies are involved in the field of medical and biotechnological research and production and distribution of the results of the research and development done in these areas.
14GF Score
Get the complete analysis for HSITF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSITF has been successfully added to your 
